Strides Pharma — 360° view

Strides Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹1,430 crore and net profit of ₹134 crore for the September 2026 quarter.

Strides Pharma (NSE: STAR) closed at ₹967.30 on 20 Nov 2026, up 4.8% over the past year. Its market capitalisation is ₹8,917 crore and it trades at 15.5 times earnings.

Share price
₹967.30 (20 Nov 2026)
Market cap
₹8,917 Cr (20 Nov 2026)
P/E
15.46 (20 Nov 2026)
Revenue
₹1,430 Cr (September 2026 quarter)
Net profit
₹134 Cr (September 2026 quarter)
ROCE
18.3% (FY26)
ROE
20.0% (FY26)
Book value
₹371 (FY26)
Dividend yield
0.52% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,260.90 / ₹768.65 (20 Nov 2026)
1-year return
4.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: STAR

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.